NCT04684459
Dual-targeting HER2 and PD-L1 CAR-T for Solid Tumors
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
- Notable Primary completion date: Dec 30, 2024 to Dec 30, 2025
- Eligibility criteria expanded, about 50 words
- Study title shortened, about 4 words
- Notable Primary completion date: Jan 1, 2023 to Dec 30, 2024
- Study completion date: Jan 1, 2024 to Dec 30, 2025
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised
- Minor Trial status: Not Yet Recruiting to Active, Not Recruiting
- Start date changed from estimate of Jan 1, 2021 to Mar 12, 2021
- Site contact updated
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Treatment-Related Adverse Events
Timeframe: 12 months
Dose-limiting toxicity (DLT)
Timeframe: 12 months
Secondary (2)
ORR(objective response rate)
DOR (duration of response)
Arms and interventions
CAR-T cell therapyExperimental
Dual-targeting HER2 and PD-L1 CAR-T cell therapy
Biologicals: Dual-targeting HER2 and PD-L1 CAR-T cells
Sites
1 site in 1 country
- West China Hospital, Sichuan UniversityChengdu, Sichuan, China